The expression of CYP2W1 in colorectal primary tumors, corresponding lymph node metastases and liver metastases

Figures & data

Figure 1. Survival in months after primary surgery in the group with low (group 1) versus high (group 2) expression of CYP2W1. HR 1.3, p = 0.38, 95% CI 0.72–2.38.

Table I. CYP2W1 expression in primary colorectal tumors and liver metastases in relation to patient and tumor characteristics. Definition of synchronous metastasis is detection within 6 months after the detection of the primary tumor.

	Number of patients	CYP2W1 expression Primary tumor, low vs. high	χ² p-value	CYP2W1 expression Liver metastases, low vs. high	χ² p-value
Total	96	71 (74%) vs. 25 (26%)		50 (52%) vs. 46 (48%)
Gender			0.86		0.26
Male	59 (61%)	44 (74%) vs. 15 (26%)		28 (47%) vs. 31 (53%)
Female	37 (39%)	27 (73%) vs. 10 (27%)		22 (59%) vs. 15 (41%)
Age			0.62		0.23
< 63	42 (44%)	30 (71%) vs. 12 (29%)		19 (45%) vs. 23 (55%)
≥ 63	54 (56%)	41 (76%) vs. 13 (24%)		31 (57%) vs. 23 (43%)
Stage			0.52		0.38
II	15 (16%)	12 (80%) vs. 3 (20%)		7 (47%) vs. 8 (53%)
III	25 (26%)	20 (80%) vs. 5 (20%)		15 (60%) vs. 9 (40%)
IV	56 (58%)	39 (70%) vs. 17 (30%)		27 (48%) vs. 29 (52%)
Tumor site			0.90		0.29
Colon	51 (53%)	38 (75%) vs. 13 (25%)		24 (47%) vs. 27 (53%)
Rectum	45 (47%)	33 (73%) vs. 12 (27%)		26 (58%) vs. 19 (42%)
Differentiation			0.74		0.59
Poor	18 (19%)	12 (67%) vs. 6 (33%)		10 (55%) vs. 8 (45%)
Moderate	74 (77%)	56 (76%) vs. 18 (24%)		37 (50%) vs. 37 (50%)
Well	4 (4%)	3 (75%) vs. 1 (25%)		3 (75%) vs. 1 (25%)
Nodes analyzed			0.62		0.38
< 13	42 (44%)	30 (71%) vs. 12 (29%)		24 (57%) vs. 18 (43%)
≥ 13	54 (56%)	41 (76%) vs. 13 (24%)		26 (48%) vs. 28 (52%)
Range 3–50
Neoadjuvant before primary operation			0.91		0.31
No	47 (49%)	35 (74%) vs. 12 (26%)		22 (47%) vs. 25 (53%)
Yes	49 (51%)	36 (73%) vs. 13 (27%)		28 (57%) vs. 21 (43%)
Type of neoadjuvant			0.11		0.08
None	47 (49%)	35 (74%) vs. 12 (26%)		22 (47%) vs. 25 (53%)
Radiation	27 (28%)	23 (85%) vs. 4 (15%)		19 (70%) vs. 8 (30%)
Radiochemo	11 (11.5%)	5 (45%) vs. 6 (54%)		3 (28%) vs. 8 (72%)
Chemo	11 (11.5%)	8 (72%) vs. 3 (28%)		6 (54%) vs. 5 (45%)
Liver metastases			0.13		0.11
Synchronous (≤ 6 months)	61 (64%)	42 (69%) vs. 19 (31%)		28 (46%) vs. 33 (54%)
Metachronous (> 6 months)	35 (36%)	29 (83%) vs. 6 (17%)		22 (63%) vs. 13 (37%)
Chemo before liver operation					0.06
No	41 (43%)			26 (63%) vs. 15 (37%)
Yes	55 (57%)			24 (44%) vs. 31 (56%)

Figure 2. Change in CYP2W1 expression between primary tumor and first liver metastasis. “Low CYP2W1 expression” corresponds to the number of tumors with immunostaining grade 0–2 while “High CYP2W1” means the number of tumors with grade 3 staining. n = 96.

Table II. Distribution of CYP2W1 expression in 96 colorectal cancer patients with liver metastasis.

Localization of high CYP2W1 expression	Number of patients Total n = 96	%
In primary tumor only	3	3.1
In primary + nodal metastasis	4	4.2
In primary + liver metastasis	12	12.5
In primary + nodes + liver	6	6.3
In nodal metastasis only	3	3.1
In nodes + liver metastasis	5	5.2
In liver metastasis only	23	24.0
Σ In primary tumor	25	26.0
Σ In nodal metastasis	18/59	18.8*
Σ In liver metastasis	46	47.9
No/low expression in any location	40	41.7

*Only 59 of the patients had nodal metastasis, i.e. 31% of nodal metastasis expressed high levels of CYP2W1.